Iovance Biotherapeutics, Inc.
(NASDAQ : IOVA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
ARRYArray BioPharma Inc.
0.16%46.508.1%$739.78m
AMGNAmgen Inc.
0.32%176.691.3%$505.23m
CELGCelgene Corporation
0.01%91.771.3%$444.24m
GILDGilead Sciences, Inc.
-1.41%67.110.9%$405.67m
BIIBBiogen Inc.
-0.33%232.841.3%$386.37m
ILMNIllumina, Inc.
-0.06%302.103.5%$335.57m
REGNRegeneron Pharmaceuticals, Inc.
-0.13%297.802.6%$277.78m
SRPTSarepta Therapeutics, Inc.
-2.84%152.4514.7%$202.93m
ALXNAlexion Pharmaceuticals, Inc.
0.58%123.762.0%$199.31m
VRTXVertex Pharmaceuticals Incorporated
0.09%176.531.9%$187.65m
EXASExact Sciences Corporation
-0.29%115.8524.1%$140.08m
AAgilent Technologies, Inc.
-1.12%69.761.6%$133.75m
INCYIncyte Corporation
-1.32%80.322.5%$114.57m
BLUEBluebird Bio, Inc.
-1.55%133.6514.3%$97.67m
BMRNBioMarin Pharmaceutical Inc.
-1.86%82.434.3%$87.70m

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.